Refine
Year of publication
Document Type
- Doctoral Thesis (42)
- Article (33)
Is part of the Bibliography
- no (75)
Keywords
- - (26)
- Staphylococcus aureus (15)
- Sepsis (9)
- <i>Staphylococcus aureus</i> (4)
- Antikörper (4)
- IgE (4)
- Immunreaktion (4)
- Immunsuppression (4)
- Immunsystem (4)
- allergy (4)
- vaccine (4)
- BALB/c Maus (3)
- Impfstoff (3)
- JSNZ (3)
- Maus (3)
- Regulatorischer T-Lymphozyt (3)
- T-Lymphozyt (3)
- sepsis (3)
- Allergie (2)
- Antibody response (2)
- Apoptose (2)
- Bakteriämie (2)
- COVID-19 (2)
- DEREG (2)
- Foxp3 (2)
- Genotypisierung (2)
- Granulozyt (2)
- Immunoglobulin G (2)
- Immunoglobulin M (2)
- IsdB (2)
- Methylene blue (2)
- Monozyt (2)
- Pathogen inactivation (2)
- S. aureus (2)
- SplB (2)
- Stress (2)
- Superantigen (2)
- Surgery (2)
- T cell (2)
- T-Zellen (2)
- Th2 (2)
- Tumor (2)
- Zelltod (2)
- colonization (2)
- host adaptation (2)
- infection (2)
- innate immunity (2)
- mouse models (2)
- neutrophils (2)
- platelets (2)
- 3-dioxygenase (1)
- <i>S. aureus</i> (1)
- <i>Streptococcus mutans</i> (1)
- <i>Streptococcus oralis</i> (1)
- A20 (1)
- ATA (1)
- Airway inflammation (1)
- Allergen (1)
- Allergic diseases (1)
- Allergy (1)
- Antigenpräsentation (1)
- Antikörperantworten (1)
- B cell response (1)
- B-Zelle (1)
- BALB/c mouse (1)
- Bacteria (1)
- Bacterial allergens (1)
- Bakteriologie (1)
- Bauchfellentzündung (1)
- Bauchspeicheldrüsenkrebs (1)
- Blood compatibility test (1)
- Blood supply (1)
- C57 BL/6 mice (1)
- C57BL/6 Maus (1)
- CASP (1)
- CD38 antibody (1)
- CD4 (1)
- CTLA-4 (1)
- Card-ii-Omics (1)
- Carrier (1)
- Chlamydia (1)
- ClfA (1)
- Coombs test (1)
- Corticosteron (1)
- Cystic Fibrosis (1)
- Cystic fibrosis (1)
- Cytokine (1)
- Cytokines (1)
- Daratumumab (1)
- Demographic change (1)
- Dendritische Zelle (1)
- Diabetes mellitus (1)
- Donor research (1)
- Effects of blood donation (1)
- Enterotoxin Gene Cluster (1)
- Entzündung (1)
- Erkundungsverhalten (1)
- FcγRIIa (1)
- FnBPA (1)
- Fragebogen (1)
- Furunkulose (1)
- GATA1 (1)
- GWA (1)
- Gel card (1)
- GlpQ (1)
- Glucocorticosteroide (1)
- HDI (1)
- HEK cells (1)
- HLA (1)
- HLA-DR (1)
- Histondeacetylase-Inhibitor (1)
- Host Pathogen Interactions (1)
- Human (1)
- Humanbiologie (1)
- IDO1 (1)
- IL-10 (1)
- IL-33 (1)
- IgG (1)
- IgG4 (1)
- IgM (1)
- Immobilisation (1)
- Immunantwort (1)
- Immune modulation (1)
- Immune response (1)
- Immunglobulin G (1)
- Immunglobuline (1)
- Immunisierung (1)
- Immunmodulation (1)
- Immunologie (1)
- Immunregulation (1)
- Immunstimulation (1)
- Immuntherapie (1)
- Indirect antiglobulin test (1)
- Indolamin-2 (1)
- Infektionen (1)
- Infektionsmodelle (1)
- Inflammation (1)
- Inselzelltransplantation (1)
- Kaltes Plasma (1)
- Kolonisierung (1)
- Kynurenin (1)
- Körperbild (1)
- LC-MS/MS (1)
- LPS (1)
- Leukozyten (1)
- Lipoprotein (1)
- Lymphozyt (1)
- MHC (1)
- MRI (1)
- MS-275 (1)
- MSCRAMM (1)
- Macrophage (1)
- Magen (1)
- Makrophage (1)
- Massenspektrometrie (1)
- Mausmodell (1)
- Mausstammvergleich (1)
- Mood regulation (1)
- Mouse model (1)
- Mukoviszidose (1)
- NETose (1)
- NETosis (1)
- NETs (1)
- NF-kappaB Signalweg (1)
- NF-kappaB pathway (1)
- NK-Cells (1)
- NK-Zellen (1)
- NLRP3 inflammasome (1)
- NOD Maus (1)
- NOD mouse (1)
- NaB (1)
- Natürliche Killerzelle (1)
- Neuroendokrines System (1)
- Neutrophile (1)
- Newcastle disease Virus (1)
- Niereninsuffizienz (1)
- Noradrenalin (1)
- Onkolyse (1)
- Operation (1)
- PBMC (1)
- PF4 (1)
- PTMs (1)
- Panton-Valentin-Leukozidin (1)
- Panton-Valentine Leukocidin (1)
- Peritonitis (1)
- Plasmamedizin (1)
- Polymerase-Kettenreaktion (1)
- Polytrauma (1)
- Postoperative immune suppression (1)
- Psychischer Stress (1)
- RBC antibody screening (1)
- Red blood cell concentrates (1)
- Reserpin (1)
- SAHA (1)
- Schlaganfall (1)
- Serine protease-like proteins (1)
- Solid phase (1)
- Sozialverhalten (1)
- SplD (1)
- Staphyloccus aureus (1)
- Staphylococci (1)
- Surgically induced immune dysfunction (1)
- Sympathikus (1)
- Systemic infection (1)
- T cell superallergen (1)
- T cells (1)
- T-cells (1)
- TLR4 (1)
- TNFAIP3 (1)
- TSST-1 (1)
- Th2 cells (1)
- Therapeutic antibody interference (1)
- Tierversuch (1)
- Toll-like-Rezeptor (1)
- Transkriptomanalyse (1)
- Translokation (1)
- Transportstress (1)
- Trauma (1)
- Tryptophan (1)
- Tryptophanstoffwechsel (1)
- Virotherapie (1)
- Western Blot Verfahren (1)
- Wirtsadaptation (1)
- Wundheilung (1)
- Zystische Fibrose (1)
- aPF4/H antibodies (1)
- activation status (1)
- acute stress (1)
- adaptive Immunantwort (1)
- adaptive Immunität (1)
- adaptive immunity (1)
- adaptives Immunsystem (1)
- adhesion inhibitor (1)
- adjuvants (1)
- akuter Stress (1)
- alpha-toxin (1)
- anti- (1)
- antibody (1)
- antibody repertoire (1)
- antibody response (1)
- antibody-secreting cells (1)
- anti‐PF4/heparin antibodies (1)
- apoptosis (1)
- asthma (1)
- atomic force microscopy (1)
- aurintricarboxylic acid (1)
- autoimmune (1)
- bakterielle Infektion (1)
- bakterielle Translokation (1)
- bleeding (1)
- bleeding tendency (1)
- blood platelets (1)
- blood smear (1)
- body image (1)
- bone marrow transplantation (1)
- case report (1)
- cell elasticity (1)
- cerebral thrombosis (1)
- chemotherapy (1)
- chirurgisch (1)
- clonal complex (1)
- coagulation (1)
- cold physical plasma (1)
- complication (1)
- cystic fibrosis (1)
- cytokines (1)
- dendritic cells (1)
- depressionsähnliches Verhalten (1)
- dirty mouse (1)
- egc superantigens (1)
- egc-Superantigene (1)
- enterotoxin gene cluster (1)
- eosinophils (1)
- epidemiology (1)
- expression (1)
- factor analysis (1)
- foxp3 (1)
- furunculosis (1)
- genotyping (1)
- gut epithelial (1)
- habitat (1)
- haemorrhage (1)
- hereditary thrombocytopenias (1)
- host-pathogen-interaction (1)
- immune evasion (1)
- immune evasion cluster (1)
- immune polarization (1)
- immunoediting (1)
- immunofluorescence (1)
- immunoglobulin g (1)
- immunoproteomics (1)
- immunosuppression (1)
- immunosupression (1)
- indoleamine 2,3-dioxygenase (1)
- infective endocarditis (1)
- infective endocarditis, antibody response, monoclonal antibodies, S. aureus, SplB, ClfA, FnBPA, Card-ii-Omics (1)
- inherited platelet defects (1)
- inherited platelet disorders (1)
- innate lymphoid cells (1)
- interaction (1)
- islet transplantation (1)
- jep Gene (1)
- kynurenine pathway (1)
- laboratory (1)
- length (1)
- leucocytes (1)
- livestock (1)
- major surgery (1)
- mass spectrometry (1)
- methyltryptophan (1)
- mixed chimerism (1)
- monoclonal antibodies (1)
- monocyte (1)
- mouse (1)
- multi-species biofilm (1)
- multiple myeloma (1)
- mupirocin (1)
- nanoindentation (1)
- nasale Besiedlung (1)
- neutralisierende Antikörper (1)
- neutralizing antibodies (1)
- nose (1)
- oxidation-specific epitopes (1)
- pathogen-specific IgG (1)
- peritonitis (1)
- phagocyte oxidase (1)
- phagocytes (1)
- phosphoproteomics (1)
- pig (1)
- plasma medicine (1)
- platelet factor 4 (1)
- platelet pathophysiology (1)
- platelet transfusion proteomics (1)
- pneumonia (1)
- polymicrobial sepsis (1)
- polyreactive antibodies (1)
- precision medicine (1)
- proteomic analysis (1)
- questionnaire (1)
- rat (1)
- re-establishment of macrophages (1)
- reactive oxygen species (1)
- regulatory T cells (1)
- regulatory t cells (1)
- reserpine (1)
- restraint stress (1)
- sensitization (1)
- serology (1)
- shame boundary (1)
- signaling (1)
- sodium (1)
- solid tumor models (1)
- splenectomy (1)
- stiffness (1)
- superantigen (1)
- superantigens (1)
- sympathetic nervous system (1)
- sympathische Denervierung (1)
- synthetic heparins (1)
- targeted proteomics (1)
- targeted therapy (1)
- therapeutics (1)
- thrombocytopenia (1)
- toxic shock syndrome (1)
- transcriptome (1)
- transportation stress (1)
- tryptophan metabolites (1)
- tumor surveillance (1)
- type 2 immune response (1)
- type 2 immunity (1)
- virulence (1)
- weight loss (1)
- wildling (1)
- wound healing (1)
- zweidimensionale Westernblots (1)
- γδ T cells (1)
Institute
- Institut für Immunologie u. Transfusionsmedizin - Abteilung Immunologie (75) (remove)
Publisher
- MDPI (12)
- Frontiers Media S.A. (10)
- S. Karger AG (5)
- Wiley (3)
- AO Research Institute Davos (1)
- American Society for Microbiology (ASM) (1)
- BMJ Publishing Group (1)
Therapeutische Antikörper können unerwartete Wirkungen verursachen, wenn das Zielantigen nicht nur auf den Zielzellen exprimiert wird. Ein gegen das CD38-Antigen gerichteter Antikörper, Daratumumab (DARA), wurde für die Behandlung des multiplen Myeloms entwickelt. Allerdings beeinträchtigt dieser Antikörper erheblich die Verträglichkeitsuntersuchungen zwischen Blutkonserve und Patientenplasma vor der Transfusion von Erythrozytenkonzentraten.
CD38 wird auch auf Erythrozyten (RBCs) exprimiert. Durch die Bindung von DARA an die Spendererythrozyten wird im indirekten Antihumanglobulintest (IAT) eine in vitro Unverträglichkeit mit allen Testerythrozyten angezeigt. Dies wird dadurch verursacht, dass das erforderliche Antihumanglubulin (AHG) humanes IgG bindet, unabhängig davon, welches Zielantigen dieser Antikörper hat. Infolgedessen können Agglutinationen durch transfusionsrelevante Antikörper im Patientenplasma von DARA-induzieretn Agglutinationen nicht unterschieden werden, wodurch das Risiko für akute hämolytische Transfusionsreaktionen steigt.
Daraus ergab sich die Fragestellung für meine Arbeit – eine Modifikation für den IAT zu finden, der diese Interferenz auflöst. Ich habe zwei neue Strategien verfolgt: i) die Adsorption von DARA aus dem Patientenplasma mit CD38-exprimierenden peripheren Blutzellen, ii) die Blockung der DARA-Bindungsstelle auf Erythrozyten, ohne dass die Bindung von transfusionsrelevanten erythrozytären Antikörpern behindert wird.
Für den ersten Ansatz konnte ich PBMCs als die Zellen identifizieren, die die höchste CD38 Expression zeigten. Leider konnte die Inkubation von DARA-gespiktem Plasma selbst nach mehreren Adsorptionsschritten die Interferenz im IAT nicht vollständig beseitigen. Auch die Durchführung der Methode erwies sich als nicht praktikabel für ein Routine-Diagnostiklabor. Für den zweiten Ansatz habe ich mit Hilfe von Pepsin F(ab‘)2 Fragmente von DARA hergestellt um damit die DARA-Bindungsstelle auf den Erythrozyten zu blockieren, damit das AHG nur an gebundene transfusionsrelevante Antikörper bindet. Die Zugabe von DARA F(ab´)2 Fragmenten zu den Testerythrozyten konnte die DARA-induzierten Agglutinationen im IAT verhindern und im Plasma vorhandene erythrozytäre Alloantikörper sichtbar und differenzierbar machen. Weiterhin konnte ich nachweisen, dass die Zugabe von DARA (Fab´)2 Fragmenten nicht die Sensitivität der Teste im Gelzentrifugationstest und im Capture® beeinträchtigt. Experimente mit Plasma von Myelom-Patienten vor und nach der DARA-Infusion bestätigten die Ergebnisse. Die Verwendung von F(ab‘)2 Fragmenten ist ein vielversprechendes Verfahren, um Interferenzen von therapeutischen Antikörpern im IAT der prätransfusionellen Diagnostik aufzulösen - nicht nur für Daratumumab.
Our modern understanding of the hygiene hypothesis is that bacteria are not only the cause of disease but also essential for a healthy immune response and regulation. Varied microbial exposure prenatally and in early childhood protects us from pathological immune reactions such as autoimmune diseases and allergies. Against this background, the hypothesis that bacteria can act as allergens appears paradoxical. Nevertheless, there is growing evidence that Staphylococcus aureus (S. aureus) is associated with allergic reactions and serine protease-like proteins (Spls) produced by S. aureus have been identified as pacemakers of allergic reactions. To open prospects for treatment or causal therapy in patients at risk, the underlying mechanism of allergy induction by Spls was studied, focusing on the IL-33 pathway in airway inflammation. In a murine asthma model C57BL/6 J wild-type mice were repeatedly exposed to SplD via intratracheal application. After two weeks a Th2-biased inflammatory response was observed in the airways: IL-33 and eotaxin production, eosinophilia, bronchial hyperreactivity, and goblet cell hyperplasia. Blocking IL-33 activity with its soluble receptor ST2 counteracted these effects: significantly decreased numbers of eosinophils, IL-13+ type 2 ILCs, IL-13+CD4+ T cells as well as reduced IL-5 and IL-13 production by lymph node cells were observed. This study indicates that SplD induces allergic airway inflammation via the IL-33/ST2 axis. IL-33 upregulation was not accompanied by cell death, which indicates that IL-33 may not be passively released by dying cells but actively secreted by the airway epithelium. Future identification of the physiological substrates of the Spls may help to shed light on the source of IL-33 in SplD-induced airway inflammation.
While the causes of allergy induction by S. aureus Spls were addressed by investigating the underlying mechanism, the consequences of this were also of interest: Does the pro-allergenic response to S. aureus affect patients exposed to S. aureus in their airways? Therefore, the humoral and cellular immune response against Spls was studied in cystic fibrosis (CF) patients who are more frequently colonized with S. aureus than the healthy population and suffer from frequent recurrent airway infections. In this patient cohort a Th2 shift of the Spl-specific immune response became evident, including high Spl-specific serum IgE levels, strong induction of Th2 cell differentiation and production of type 2 cytokines following ex vivo stimulation with recombinant Spls. The observed response seems to be specific for Spls rather than being a general feature of S. aureus proteases since other putative allergens of S. aureus (ScpA, SspB) did not show increased IgE binding in CF sera. The Th2-driven immune response might impede antibacterial clearance and worsen the clinical picture. Larger clinical studies are needed to validate this notion by correlating the anti-S. aureus immune response with clinical parameters and testing new therapy options.
These results and findings shed light on a novel, possibly underestimated facet of the immune response against S. aureus and give impetus for further research on bacterial allergens in general, reaching beyond the species S. aureus.
In cystic fibrosis (CF) infectious and allergic airway inflammation cause pulmonary exacerbations that destroy the lungs. Staphylococcus aureus is a common long-term colonizer and cause of recurrent airway infections in CF. The pathogen is also associated with respiratory allergy; especially the staphylococcal serine protease-like proteins (Spls) can induce type 2 immune responses in humans and mice. We measured the serum IgE levels specific to 7 proteases of S. aureus by ELISA, targeting 5 Spls (76 CF patients and 46 controls) and the staphopains A and B (16 CF patients and 46 controls). Then we compared cytokine release and phenotype of T cells that had been stimulated with Spls between 5 CF patients and 5 controls. CF patients had strongly increased serum IgE binding to all Spls but not to the staphopains. Compared to healthy controls, their Spl-stimulated T cells released more type 2 cytokines (IL-4, IL-5, IL-13) and more IL-6 with no difference in the secretion of type 1- or type 3 cytokines (IFNγ, IL-17A, IL-17F). IL-10 production was low in CF T cells. The phenotype of the Spl-exposed T cells shifted towards a Th2 or Th17 profile in CF but to a Th1 profile in controls. Sensitization to S. aureus Spls is common in CF. This discovery could explain episodes of allergic inflammation of hitherto unknown causation in CF and extend the diagnostic and therapeutic portfolio.
: Platelets are components of the blood that are highly reactive, and they quickly respond
to multiple physiological and pathophysiological processes. In the last decade, it became clear that
platelets are the key components of circulation, linking hemostasis, innate, and acquired immunity.
Protein composition, localization, and activity are crucial for platelet function and regulation. The
current state of mass spectrometry-based proteomics has tremendous potential to identify and quantify thousands of proteins from a minimal amount of material, unravel multiple post-translational
modifications, and monitor platelet activity during drug treatments. This review focuses on the role
of proteomics in understanding the molecular basics of the classical and newly emerging functions
of platelets. including the recently described role of platelets in immunology and the development
of COVID-19.The state-of-the-art proteomic technologies and their application in studying platelet
biogenesis, signaling, and storage are described, and the potential of newly appeared trapped ion
mobility spectrometry (TIMS) is highlighted. Additionally, implementing proteomic methods in
platelet transfusion medicine, and as a diagnostic and prognostic tool, is discussed.
Background and Objectives: Vaccine induced thrombotic thrombocytopenia (VITT) may occur after COVID-19 vaccination with recombinant adenoviral vector-based vaccines. VITT can present as cerebral sinus and venous thrombosis (CSVT), often complicated by intracranial hemorrhage. Today it is unclear, how long symptomatic VITT can persist. Here, we report the complicated long-term course of a VITT patient with extremely high titers of pathogenic anti-platelet factor 4 (PF4)-IgG antibodies. Methods: Clinical and laboratory findings are presented, including the course of platelet counts, D-Dimer levels, clinical presentation, imaging, SARS-CoV-2-serological and immunological, platelet activating anti-PF4-IgG, as well as autopsy findings. Results: The patient presented with extended superior sagittal sinus thrombosis with accompanying bifrontal intracerebral hemorrhage. Repeated treatment with intravenous immune globuline (IVIG) resolved recurrent episodes of thrombocytopenia. Moreover, the patient’s serum remained strongly positive for platelet-activating anti-PF4-IgG over three months. After a period of clinical stabilization, the patient suffered a recurrent and fatal intracranial hemorrhage. Conclusions: Complicated VITT with extremely high anti-PF4-IgG titers over three months can induce recurrent thrombocytopenia despite treatment with IVIG and anticoagulation. Plasma exchange, immunoadsorption, and /or immunosuppressive treatment may be considered in complicated VITT to reduce extraordinarily high levels of anti-PF4-IgG. Long-term therapy in such cases must take the individual bleeding risk and CSVT risk into account.
High Na+ Environments Impair Phagocyte Oxidase-Dependent Antibacterial Activity of Neutrophils
(2021)
Infection and inflammation can augment local Na+ abundance. These increases in local Na+ levels boost proinflammatory and antimicrobial macrophage activity and can favor polarization of T cells towards a proinflammatory Th17 phenotype. Although neutrophils play an important role in fighting intruding invaders, the impact of increased Na+ on the antimicrobial activity of neutrophils remains elusive. Here we show that, in neutrophils, increases in Na+ (high salt, HS) impair the ability of human and murine neutrophils to eliminate Escherichia coli and Staphylococcus aureus. High salt caused reduced spontaneous movement, degranulation and impaired production of reactive oxygen species (ROS) while leaving neutrophil viability unchanged. High salt enhanced the activity of the p38 mitogen-activated protein kinase (p38/MAPK) and increased the interleukin (IL)-8 release in a p38/MAPK-dependent manner. Whereas inhibition of p38/MAPK did not result in improved neutrophil defense, pharmacological blockade of the phagocyte oxidase (PHOX) or its genetic ablation mimicked the impaired antimicrobial activity detected under high salt conditions. Stimulation of neutrophils with phorbol-12-myristate-13-acetate (PMA) overcame high salt-induced impairment in ROS production and restored antimicrobial activity of neutrophils. Hence, we conclude that high salt-impaired PHOX activity results in diminished antimicrobial activity. Our findings suggest that increases in local Na+ represent an ionic checkpoint that prevents excessive ROS production of neutrophils, which decreases their antimicrobial potential and could potentially curtail ROS-mediated tissue damage.
Introduction: In the light of the ongoing SARS-CoV-2 pandemic, convalescent plasma is a treatment option for COVID-19. In contrast to usual therapeutic plasma, the therapeutic agents of convalescent plasma do not represent clotting factor activities, but immunoglobulins. Quarantine storage of convalescent plasma as a measure to reduce the risk of pathogen transmission is not feasible. Therefore, pathogen inactivation (e.g., Theraflex®-MB, Macopharma, Mouvaux, France) is an attractive option. Data on the impact of pathogen inactivation by methylene blue (MB) treatment on antibody integrity are sparse. Methods: Antigen-specific binding capacity was tested before and after MB treatment of plasma (n = 10). IgG and IgM isoagglutinin titers were tested by agglutination in increasing dilutions. Furthermore, the binding of anti-EBV and anti-tetanus toxin IgG to their specific antigens was assessed by ELISA, and IgG binding to Fc receptors was assessed by flow cytometry using THP-1 cells expressing FcRI and FcRII. Results: There was no significant difference in the isoagglutinin titers, the antigen binding capacity of anti-EBV and anti-tetanus toxin IgG, as well as the Fc receptor binding capacity before and after MB treatment of plasma. Conclusion: MB treatment of plasma does not inhibit the binding capacity of IgM and IgG to their epitopes, or the Fc receptor interaction of IgG. Based on these results, MB treatment of convalescent plasma is appropriate to reduce the risk of pathogen transmission if quarantine storage is omitted.
Protection against Staphylococcus aureus is determined by the polarization of the anti-bacterial immune effector mechanisms. Virulence factors of S. aureus can modulate these and induce differently polarized immune responses in a single individual. We proposed that this may be due to intrinsic properties of the bacterial proteins. To test this idea, we selected two virulence factors, the serine protease-like protein B (SplB) and the glycerophosphoryl diester phosphodiesterase (GlpQ). In humans naturally exposed to S. aureus, SplB induces a type 2-biased adaptive immune response, whereas GlpQ elicits type 1/type 3 immunity. We injected the recombinant bacterial antigens into the peritoneum of S. aureus-naïve C57BL/6N mice and analyzed the immune response. This was skewed by SplB toward a Th2 profile including specific IgE, whereas GlpQ was weakly immunogenic. To elucidate the influence of adjuvants on the proteins’ polarization potential, we studied Montanide ISA 71 VG and Imject™Alum, which promote a Th1 and Th2 response, respectively. Alum strongly increased antibody production to the Th2-polarizing protein SplB, but did not affect the response to GlpQ. Montanide enhanced the antibody production to both S. aureus virulence factors. Montanide also augmented the inflammation in general, whereas Alum had little effect on the cellular immune response. The adjuvants did not override the polarization potential of the S. aureus proteins on the adaptive immune response.